1. Home
  2. TAK
  3. TAK News

Latest Takeda Pharmaceutical Company Limited (each representing 1/2 of a share of) (TAK) News on September 17, 2025

Takeda and VELA to Ship Medicines Across the Atlantic Using First-of-its-Kind Wind-Powered Trimaran
TAK

Business Wire

14 hours ago

Takeda and VELA to Ship Medicines Across the Atlantic Using First-of-its-Kind Wind-Powered Trimaran

From atop Mt. Fuji, a Takeda team heralds a need for human plasma
TAK

Pharma Voice

18 hours ago

From atop Mt. Fuji, a Takeda team heralds a need for human plasma

Takeda poaches top Lilly exec; Maze soars on early PKU drug data
TAK

BioPharma Dive

5 days ago

Takeda poaches top Lilly exec; Maze soars on early PKU drug data

Takeda Pharmaceutical (TSE:4502) Prepares For Leadership Transition With New Executives
TAK

Simply Wall St.

5 days ago

Takeda Pharmaceutical (TSE:4502) Prepares For Leadership Transition With New Executives

Takeda Appoints Rhonda Pacheco President of the U.S. Business Unit
TAK

Business Wire

6 days ago

Takeda Appoints Rhonda Pacheco President of the U.S. Business Unit

Assessing Takeda Stock After Recent 6% Jump and New FDA Approval for HyQvia Expansion
TAK

Simply Wall St.

8 days ago

Assessing Takeda Stock After Recent 6% Jump and New FDA Approval for HyQvia Expansion

Takeda and Alkermes share OX2R drug data for narcolepsy
TAK

Clinical Trials Arena

8 days ago

Takeda and Alkermes share OX2R drug data for narcolepsy

A new class of sleep drugs draws Wall Street’s attention
TAK

BioPharma Dive

8 days ago

A new class of sleep drugs draws Wall Street’s attention

Takeda (TSE:4502) Valuation in Focus After Narcolepsy Trial Success and VONVENDI FDA Expansion
TAK

Simply Wall St.

8 days ago

Takeda (TSE:4502) Valuation in Focus After Narcolepsy Trial Success and VONVENDI FDA Expansion

TAK

MT Newswires

9 days ago

Takeda Gets FDA Approval for Expanded Label for Bleeding Disorder Therapy

Takeda Presents Orexin Data from Landmark Oveporexton (TAK-861) Phase 3 Program in Narcolepsy Type 1 at World Sleep 2025
TAK

Business Wire

9 days ago

Takeda Presents Orexin Data from Landmark Oveporexton (TAK-861) Phase 3 Program in Narcolepsy Type 1 at World Sleep 2025

U.S. FDA Approves Expanded Indication for VONVENDI® [von Willebrand factor (Recombinant)] for Adults and Children with Von Willebrand Disease
TAK

Business Wire

11 days ago

U.S. FDA Approves Expanded Indication for VONVENDI® [von Willebrand factor (Recombinant)] for Adults and Children with Von Willebrand Disease

TAK

MT Newswires

13 days ago

Novavax Says COVID-19 Vaccine Approval in Japan Triggers Takeda Milestone Payment

Nuvaxovid® Now Approved in Japan Triggering Takeda Milestone Payment
TAK

PR Newswire

13 days ago

Nuvaxovid® Now Approved in Japan Triggering Takeda Milestone Payment

Nicotine Gum Market Report 2025-2033 | Competitive Analysis of British American Tobacco, Cambrex, GlaxoSmithKline, ITC, Johnson & Johnson, Novartis, Perrigo, Pfizer, and Takeda
TAK

GlobeNewswire

15 days ago

Nicotine Gum Market Report 2025-2033 | Competitive Analysis of British American Tobacco, Cambrex, GlaxoSmithKline, ITC, Johnson & Johnson, Novartis, Perrigo, Pfizer, and Takeda

TAK

MT Newswires

20 days ago

Takeda Pharmaceutical Says Fruzaqla Included in Reimbursable Medicines in Quebec, Canada

Takeda's FRUZAQLA™ (fruquintinib) publicly reimbursed in Quebec for the treatment of metastatic colorectal cancer (mCRC)
TAK

CNW Group

20 days ago

Takeda's FRUZAQLA™ (fruquintinib) publicly reimbursed in Quebec for the treatment of metastatic colorectal cancer (mCRC)

Takeda Pharmaceutical Company Limited (TAK) Advances γδ T Cell Cancer Treatments
TAK

Insider Monkey

20 days ago

Takeda Pharmaceutical Company Limited (TAK) Advances γδ T Cell Cancer Treatments

Binge Eating Disorders Global Market Research Report 2025-2035 Featuring Eli Lilly, Amneal, Takeda, Tryp Therapeutics, Tonix, Sumitomo, VIVUS, Novartis, and Pfize
TAK

GlobeNewswire

21 days ago

Binge Eating Disorders Global Market Research Report 2025-2035 Featuring Eli Lilly, Amneal, Takeda, Tryp Therapeutics, Tonix, Sumitomo, VIVUS, Novartis, and Pfize

Medical Affairs Leader Dr. Kirk Shepard Joins BP Logix’s Life Sciences Strategic Advisory Board
TAK

Business Wire

22 days ago

Medical Affairs Leader Dr. Kirk Shepard Joins BP Logix’s Life Sciences Strategic Advisory Board

TAK

MT Newswires

23 days ago

Protagonist Therapeutics Says Rusfertide Gets US FDA Breakthrough Therapy Designation for Blood Condition Treatment

TAK

MT Newswires

a month ago

Veeva Systems Q2 Results Likely In-Line to Better, Maintain H2 Outlook, Truist Says

US eosinophilic oesophagitis market to reach $1.19bn by 2030
TAK

Pharmaceutical Technology

a month ago

US eosinophilic oesophagitis market to reach $1.19bn by 2030

Multiple Myeloma Market Trends and Company Analysis Report 2025-2033 Featuring BMS, Novartis, Abbvie, Sanofi, Johnson and Johnson, Baxter, Pfizer, and Takeda
TAK

GlobeNewswire

a month ago

Multiple Myeloma Market Trends and Company Analysis Report 2025-2033 Featuring BMS, Novartis, Abbvie, Sanofi, Johnson and Johnson, Baxter, Pfizer, and Takeda

US Personalized Medicine Market Trends and Company Analysis Report 2025-2033 Featuring Abbott, GE, Aadi Bioscience, Illumina, QIAGEN, Eli Lilly and Co, Takeda, AbbVie, F. Hoffmann-La Roche
TAK

GlobeNewswire

a month ago

US Personalized Medicine Market Trends and Company Analysis Report 2025-2033 Featuring Abbott, GE, Aadi Bioscience, Illumina, QIAGEN, Eli Lilly and Co, Takeda, AbbVie, F. Hoffmann-La Roche

IBAT Inhibitors Market Witnesses Strong Growth During the Forecast Period (2025-2034) Owing to the Rising Demand for Rare Cholestatic Liver Disease Therapies | DelveInsight
TAK

PR Newswire

a month ago

IBAT Inhibitors Market Witnesses Strong Growth During the Forecast Period (2025-2034) Owing to the Rising Demand for Rare Cholestatic Liver Disease Therapies | DelveInsight

Multiple Myeloma Global and Regional Market Analysis and Forecast Report 2025-2035 | Johnson & Johnson, Sanofi, AbbVie, Bristol-Myers Squibb, Takeda, Pfizer Drive Innovation and Growth
TAK

GlobeNewswire

a month ago

Multiple Myeloma Global and Regional Market Analysis and Forecast Report 2025-2035 | Johnson & Johnson, Sanofi, AbbVie, Bristol-Myers Squibb, Takeda, Pfizer Drive Innovation and Growth

TAK

Newsfile

a month ago

Cosmo and Takeda Renew Strategic Manufacturing Agreement for Global Supply of Oral Treatment for Ulcerative Colitis

United States Pharmaceutical Market Forecast and Company Analysis Report 2025-2033 Featuring F. Hoffmann-La Roche, Novartis, Abbvie, Johnson & Johnson, Merck, Pfizer, BMS, Sanofi, GSK, Takeda
TAK

GlobeNewswire

a month ago

United States Pharmaceutical Market Forecast and Company Analysis Report 2025-2033 Featuring F. Hoffmann-La Roche, Novartis, Abbvie, Johnson & Johnson, Merck, Pfizer, BMS, Sanofi, GSK, Takeda

Novavax banks on vaccine supply partnerships to boost 2025 revenue
TAK

Reuters

a month ago

Novavax banks on vaccine supply partnerships to boost 2025 revenue

Novavax Reports Second Quarter 2025 Financial Results and Operational Highlights
TAK

PR Newswire

a month ago

Novavax Reports Second Quarter 2025 Financial Results and Operational Highlights

Fresenius Kabi signs global licensing deal for Polpharma’s vedolizumab biosimilar
TAK

Pharmaceutical Technology

a month ago

Fresenius Kabi signs global licensing deal for Polpharma’s vedolizumab biosimilar

Blackstone Plans to Take Japan’s TechnoPro Private
TAK

The Wall Street Journal

a month ago

Blackstone Plans to Take Japan’s TechnoPro Private

TYK2 Inhibitors Market to Drive Enormous Growth by 2034 Due to Strong Pipeline and Expanding Indications | DelveInsight
TAK

PR Newswire

a month ago

TYK2 Inhibitors Market to Drive Enormous Growth by 2034 Due to Strong Pipeline and Expanding Indications | DelveInsight

Denmark Pharmaceutical Market Forecast and Company Analysis Report 2025-2033 Featuring Novo Nordisk, H. Lundbeck, Leo, Orifarm, ALK-Abell, Xellia, Takeda, Sandoz, Ferring Pharmaceuticals, FUJIFILM
TAK

GlobeNewswire

a month ago

Denmark Pharmaceutical Market Forecast and Company Analysis Report 2025-2033 Featuring Novo Nordisk, H. Lundbeck, Leo, Orifarm, ALK-Abell, Xellia, Takeda, Sandoz, Ferring Pharmaceuticals, FUJIFILM

Xoma strikes deals to buy struggling biotechs HilleVax, Lava
TAK

BioPharma Dive

a month ago

Xoma strikes deals to buy struggling biotechs HilleVax, Lava

Renal Failure Clinical Trials Market Landscape Report 2025 Featuring Bayer, AstraZeneca, Amgen, Sanofi, Novartis, AbbVie, Roche, Pfizer, Takeda, Astellas
TAK

GlobeNewswire

2 months ago

Renal Failure Clinical Trials Market Landscape Report 2025 Featuring Bayer, AstraZeneca, Amgen, Sanofi, Novartis, AbbVie, Roche, Pfizer, Takeda, Astellas

Mycosis Fungoides Clinical Trials Market Landscape Report 2025 Featuring Pfizer, Bristol-Myers Squibb, Kirin, Takeda, Johnson & Johnson, Merck, Soligenix, Eisai, Novartis, ICON
TAK

GlobeNewswire

2 months ago

Mycosis Fungoides Clinical Trials Market Landscape Report 2025 Featuring Pfizer, Bristol-Myers Squibb, Kirin, Takeda, Johnson & Johnson, Merck, Soligenix, Eisai, Novartis, ICON

Takeda Pharma Maintains Outlook Even As Vyvanse Generics Hit Sales
TAK

Benzinga

2 months ago

Takeda Pharma Maintains Outlook Even As Vyvanse Generics Hit Sales

TAK

MT Newswires

2 months ago

Takeda Pharmaceutical Fiscal Q1 Core Earnings, Revenue Fall; Reiterates Fiscal 2025 Guidance

Takeda Announces First-Quarter FY2025 Results With Significant Late-Stage Pipeline Progression
TAK

Business Wire

2 months ago

Takeda Announces First-Quarter FY2025 Results With Significant Late-Stage Pipeline Progression

Tempus AI's Data Business Keeps Scaling Up: Can the Growth Pace Last?
TAK

Zacks

3 months ago

Tempus AI's Data Business Keeps Scaling Up: Can the Growth Pace Last?

Will Strong Asceniv Sales Drive ADMA Biologics Further?
TAK

Zacks

3 months ago

Will Strong Asceniv Sales Drive ADMA Biologics Further?

Liver Organoid Breakthrough: Generating Organ-Specific Blood Vessels
TAK

PR Newswire

3 months ago

Liver Organoid Breakthrough: Generating Organ-Specific Blood Vessels

Ocular Therapeutix (OCUL) Moves 8.6% Higher: Will This Strength Last?
TAK

Zacks

3 months ago

Ocular Therapeutix (OCUL) Moves 8.6% Higher: Will This Strength Last?

ADMA vs Takeda: Which Plasma Therapy Stock Is the Better Buy Today?
TAK

Zacks

3 months ago

ADMA vs Takeda: Which Plasma Therapy Stock Is the Better Buy Today?

Takeda Announces New Assignments of Directors
TAK

Business Wire

3 months ago

Takeda Announces New Assignments of Directors

Protagonist Therapeutics, Takeda Pharmaceutical Announce Positive Phase 3 Rusfertide Results for Polycythemia Vera
TAK

Insider Monkey

3 months ago

Protagonist Therapeutics, Takeda Pharmaceutical Announce Positive Phase 3 Rusfertide Results for Polycythemia Vera

ADMA Looks to Expand Asceniv's Label: Will This Boost Sales?
TAK

Zacks

3 months ago

ADMA Looks to Expand Asceniv's Label: Will This Boost Sales?

EC approves Takeda ADC plus chemo for stage IIb Hodgkin’s lymphoma
TAK

Pharmaceutical Technology

3 months ago

EC approves Takeda ADC plus chemo for stage IIb Hodgkin’s lymphoma

TAK

MT Newswires

3 months ago

Takeda Pharmaceutical Receives European Commission Approval for Adcetris Regimen to Treat Hodgkin Lymphoma

European Commission Approves ADCETRIS® (brentuximab vedotin) for the Treatment of Adult Patients with Newly Diagnosed Stage IIb/III/IV Hodgkin Lymphoma in Combination with ECADD
TAK

Business Wire

3 months ago

European Commission Approves ADCETRIS® (brentuximab vedotin) for the Treatment of Adult Patients with Newly Diagnosed Stage IIb/III/IV Hodgkin Lymphoma in Combination with ECADD

TAK

MT Newswires

3 months ago

Protagonist Therapeutics, Takeda's Potential Polycythemia Vera Drug Meets Primary Endpoint

TAK

Business Wire

4 months ago

Protagonist and Takeda Announce ASCO Plenary Presentation Highlighting Full 32-Week Results from Phase 3 VERIFY Study of Rusfertide, Showing Reductions in Phlebotomy, Improved Hematocrit Control in Polycythemia Vera

TAK

MT Newswires

4 months ago

Xoma Royalty Acquires Mezagitamab Royalty, Milestone Rights From BioInvent

Takeda and Nature Announce Call for Applications Now Open for 2026 Innovators in Science Award
TAK

Business Wire

4 months ago

Takeda and Nature Announce Call for Applications Now Open for 2026 Innovators in Science Award

Takeda Taps Salesforce (CRM) for AI-Driven Customer Experience Platform
TAK

Insider Monkey

4 months ago

Takeda Taps Salesforce (CRM) for AI-Driven Customer Experience Platform

TAK

MT Newswires

4 months ago

Salesforce's Life Sciences Cloud Platform Chosen by Takeda

The New England Journal of Medicine Publishes Data from Phase 2b Trial of Oral Orexin Receptor 2 Agonist Oveporexton (TAK-861) in People with Narcolepsy Type 1
TAK

Business Wire

4 months ago

The New England Journal of Medicine Publishes Data from Phase 2b Trial of Oral Orexin Receptor 2 Agonist Oveporexton (TAK-861) in People with Narcolepsy Type 1

Pharmaceutical Stocks Tumble on Trump Plan to Cut US Drug Prices
TAK

Bloomberg

4 months ago

Pharmaceutical Stocks Tumble on Trump Plan to Cut US Drug Prices

Top 4 GARP Stocks With Attractive PEG Ratios to Watch
TAK

Zacks

4 months ago

Top 4 GARP Stocks With Attractive PEG Ratios to Watch

TAK

MT Newswires

4 months ago

Sector Update: Health Care Stocks Decline Pre-Bell Thursday

TAK

MT Newswires

4 months ago

Sector Update: Health Care

TAK

MT Newswires

4 months ago

Takeda Pharmaceutical Fiscal Q4 Core Earnings Fall, Revenue Rises

Takeda Announces FY2024 Full Year Results and FY2025 Outlook Reflecting Growth & Launch Products Momentum, Strong Cash Flow Generation and Late-Stage Pipeline Progress
TAK

Business Wire

4 months ago

Takeda Announces FY2024 Full Year Results and FY2025 Outlook Reflecting Growth & Launch Products Momentum, Strong Cash Flow Generation and Late-Stage Pipeline Progress

Takeda Pharmaceutical Co. (TAK) Upgraded to Strong Buy: Here's What You Should Know
TAK

Zacks

4 months ago

Takeda Pharmaceutical Co. (TAK) Upgraded to Strong Buy: Here's What You Should Know

Should Value Investors Buy Takeda Pharmaceutical Co. (TAK) Stock?
TAK

Zacks

4 months ago

Should Value Investors Buy Takeda Pharmaceutical Co. (TAK) Stock?

What To Expect From Takeda Pharmaceutical Co Ltd (TSE:4502) Q4 2024 Earnings
TAK

GuruFocus.com

4 months ago

What To Expect From Takeda Pharmaceutical Co Ltd (TSE:4502) Q4 2024 Earnings

TAK

MT Newswires

4 months ago

Novavax Updates Financial Terms With Takeda for Covid-19 Vaccine Agreement in Japan

BioLife Plasma Services Introduces the New Fresenius Kabi Adaptive Nomogram Across its U.S. Network of Plasma Donation Centers
TAK

Business Wire

4 months ago

BioLife Plasma Services Introduces the New Fresenius Kabi Adaptive Nomogram Across its U.S. Network of Plasma Donation Centers

TAK or DSNKY: Which Is the Better Value Stock Right Now?
TAK

Zacks

4 months ago

TAK or DSNKY: Which Is the Better Value Stock Right Now?

Are You Looking for a Top Momentum Pick? Why Takeda Pharmaceutical Co. (TAK) is a Great Choice
TAK

Zacks

5 months ago

Are You Looking for a Top Momentum Pick? Why Takeda Pharmaceutical Co. (TAK) is a Great Choice

Best Value Stocks to Buy for April 30th
TAK

Zacks

5 months ago

Best Value Stocks to Buy for April 30th

Best Income Stocks to Buy for April 30th
TAK

Zacks

5 months ago

Best Income Stocks to Buy for April 30th

Takeda Awards $13.8 Million to U.S. Nonprofit Partners to Promote Healthy Eating and Expand STEM Education
TAK

Business Wire

5 months ago

Takeda Awards $13.8 Million to U.S. Nonprofit Partners to Promote Healthy Eating and Expand STEM Education

New Strong Buy Stocks for April 30th
TAK

Zacks

5 months ago

New Strong Buy Stocks for April 30th

Are Investors Undervaluing Takeda Pharmaceutical Co. (TAK) Right Now?
TAK

Zacks

5 months ago

Are Investors Undervaluing Takeda Pharmaceutical Co. (TAK) Right Now?

TAK vs. DSNKY: Which Stock Is the Better Value Option?
TAK

Zacks

5 months ago

TAK vs. DSNKY: Which Stock Is the Better Value Option?

NMPA approves BBM and Takeda China’s haemophilia B therapy
TAK

Pharmaceutical Technology

5 months ago

NMPA approves BBM and Takeda China’s haemophilia B therapy

Pharma Stocks Slide Further After Trump Reiterates Tariff Threats on Drugs
TAK

The Wall Street Journal

5 months ago

Pharma Stocks Slide Further After Trump Reiterates Tariff Threats on Drugs

Is Takeda Pharmaceutical Co. (TAK) Stock Undervalued Right Now?
TAK

Zacks

5 months ago

Is Takeda Pharmaceutical Co. (TAK) Stock Undervalued Right Now?

TAK vs. DSNKY: Which Stock Should Value Investors Buy Now?
TAK

Zacks

6 months ago

TAK vs. DSNKY: Which Stock Should Value Investors Buy Now?

Takeda Canada says Health Canada expands marketing authorization for HyQvia
TAK

TipRanks

6 months ago

Takeda Canada says Health Canada expands marketing authorization for HyQvia

TAK

MT Newswires

6 months ago

Mirum Pharmaceuticals Says Livmarli Approved in Japan for Pruritus

Takeda's HyQvia® receives expanded market authorization as maintenance therapy for chronic inflammatory demyelinating polyneuropathy (CIDP)
TAK

CNW Group

6 months ago

Takeda's HyQvia® receives expanded market authorization as maintenance therapy for chronic inflammatory demyelinating polyneuropathy (CIDP)

Is Takeda Pharmaceutical Co. (TAK) a Great Value Stock Right Now?
TAK

Zacks

6 months ago

Is Takeda Pharmaceutical Co. (TAK) a Great Value Stock Right Now?

TAK or DSNKY: Which Is the Better Value Stock Right Now?
TAK

Zacks

6 months ago

TAK or DSNKY: Which Is the Better Value Stock Right Now?

Takeda’s $770M deal deepens Big Pharma’s omics push
TAK

Pharma Voice

6 months ago

Takeda’s $770M deal deepens Big Pharma’s omics push

Takeda-Protagonist Therapeutics Partnered Investigational Drug Hits Primary Goal In Late-Stage Study In Patients With Type Of Blood Cancer
TAK

Benzinga

6 months ago

Takeda-Protagonist Therapeutics Partnered Investigational Drug Hits Primary Goal In Late-Stage Study In Patients With Type Of Blood Cancer

Takeda and Protagonist report topline outcomes from trial of rusfertide
TAK

Clinical Trials Arena

6 months ago

Takeda and Protagonist report topline outcomes from trial of rusfertide

Should Value Investors Buy Takeda Pharmaceutical Co. (TAK) Stock?
TAK

Zacks

6 months ago

Should Value Investors Buy Takeda Pharmaceutical Co. (TAK) Stock?

TAK

MT Newswires

6 months ago

Protagonist, Takeda Say Phase 3 Study of Rusfertide Meets Endpoints in Polycythemia Vera

Protagonist and Takeda Announce Positive Topline Results from Phase 3 VERIFY Study of Rusfertide in Patients with Polycythemia Vera
TAK

Business Wire

6 months ago

Protagonist and Takeda Announce Positive Topline Results from Phase 3 VERIFY Study of Rusfertide in Patients with Polycythemia Vera

Protagonist says Takeda-partnered drug succeeds in rare blood cancer
TAK

BioPharma Dive

6 months ago

Protagonist says Takeda-partnered drug succeeds in rare blood cancer

Is Takeda Pharmaceutical Company Limited (TAK) the Best Low Price Pharma Stock to Invest In Right Now?
TAK

Insider Monkey

7 months ago

Is Takeda Pharmaceutical Company Limited (TAK) the Best Low Price Pharma Stock to Invest In Right Now?

Takeda broadens its deal with BridGene for up to $770m
TAK

Pharmaceutical Technology

7 months ago

Takeda broadens its deal with BridGene for up to $770m

EMA approves Takeda’s Takhzyro pre-filled pen option for HAE
TAK

Pharmaceutical Technology

7 months ago

EMA approves Takeda’s Takhzyro pre-filled pen option for HAE

TAK

MT Newswires

7 months ago

Takeda Secures EMA Approval for Additional Injection Option for Hereditary Angioedema Drug

The European Medicines Agency (EMA) Has Approved an Additional Subcutaneous Administration Option for TAKHZYRO® (lanadelumab) for Patients Aged 12 Years and Above with Recurrent Attacks of Hereditary Angioedema (HAE)
TAK

PR Newswire

7 months ago

The European Medicines Agency (EMA) Has Approved an Additional Subcutaneous Administration Option for TAKHZYRO® (lanadelumab) for Patients Aged 12 Years and Above with Recurrent Attacks of Hereditary Angioedema (HAE)

TAK vs. DSNKY: Which Stock Is the Better Value Option?
TAK

Zacks

7 months ago

TAK vs. DSNKY: Which Stock Is the Better Value Option?

Share on Social Networks: